NEOPLASIAS HEMATOLÓGICAS: LEUCEMIAS, LINFOMAS Y MIELOMAS

Volver

Resultados 52 resultados LastUpdate Última actualización: 27/05/2016 [14:26:00] pdf PDF




Solicitudes de Patente publicadas en los últimos 30 días / Patent Applications last 30 days publications



Página 1 de 3 nextPage   Mostrar por página


Bispecific antibodies against CD3epsilon and BCMA

Nº publicación: EP3023437A1 25/05/2016

Solicitante:
ENGMAB AG [CH]

Resumen de: EP3023437A1

An antibody light chain, comprising as CDRs CDR1L of SEQ ID NO:6, CDR2L of SEQ ID NO:7, and CDR3L of SEQ ID NO:8, is useful as common light chain in a bispecific antibody specifically binding to the extracellular domain of human BCMA and human CD3.Such bispecific antibody can be used as a medicament in the treatment of plasma cell disorders like Multiple Myeloma.



traducir


 

METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES

Nº publicación: US2016137735A1 19/05/2016

Solicitantes:
ABBVIE BIOTHERAPEUTICS INC [US]
DANA FARBER CANCER INSITUTE INC [US]

Resumen de: US2008152646A1

Compositions and methods for treating MM are provided herein.



traducir


 

Molecular and Herbal Combinations for Disease Therapy

Nº publicación: US2016136218A1 19/05/2016

Solicitantes:
SHRAIBOM NADAV [IL]
SIRBAL LTD [CY]

Resumen de: US2016136218A1

A method and medicine for treating leukemia or other cancer includes administering to a patient diagnosed with leukemia or other cancer a treatment regimen that includes periodic doses of a combination including emodin or digoxin, or both, with Sheng Di Huang or Da Huang, or both, and/or Jin Yin Hua.



traducir


 

INDUCTION OF GATA2 BY HDAC1 AND HDAC2 INHIBITORS

Nº publicación: US2016137630A1 19/05/2016

Solicitante:
ACETYLON PHARMACEUTICALS INC [US]

Resumen de: WO2016057779A2

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with Gata2 deficiency, particularly diseases or disorders that involve any type of HDAC1 and/or HDAC2 expression. Such diseases include acute myeloid leukemia (AML); familial myelodysplastic syndrome (MDS); leukemia; sickle-cell anemia; beta-thalassemia; monocytopenia and mycobacterial infections; dendritic cell, nonocyte, B, and natural killer lymphoid deficiency; Emberger syndrome; asymptomatic neurocognitive impairment; mild neurocognitive disorder; and HIV- associated dementia.



traducir


 

EX VIVO HUMAN MULTIPLE MYELOMA CANCER NICHE AND ITS USE AS A MODEL FOR PERSONALIZED TREATMENT OF MULTIPLE MYELOMA

Nº publicación: US2016137986A1 19/05/2016

Solicitantes:
HACHENSACK UNIVERSITY MEDICAL CT [US]
STEVENS INST TECHNOLOGY [US]

Resumen de: US2014274953A1

The described invention provides an ex vivo dynamic multiple myeloma (MM) cancer niche contained in a microfluidic device. The dynamic MM cancer niche includes (a) a three-dimensional tissue construct containing a dynamic ex vivo bone marrow (BM) niche, which contains a mineralized bone-like tissue containing viable osteoblasts self-organized into cohesive multiple cell layers and an extracellular matrix secreted by the viable adherent osteoblasts; and a microenvironment dynamically perfused by nutrients and dissolved gas molecules; and (b) human myeloma cells seeded from a biospecimen composition comprising mononuclear cells and the multiple myeloma cells. The human myeloma cells are in contact with osteoblasts of the BM niche, and the viability of the human myeloma cells is maintained by the MM cancer niche.



traducir


 

METHODS FOR DETECTING AND TREATING MULTIPLE MYELOMA

Nº publicación: US2016138109A1 19/05/2016

Solicitante:
ANDES BIOTECHNOLOGIES S A [CL]

Resumen de: WO2014153206A2

The invention provides methods for using the expression levels and subcellular localization of non-coding mitochondrial RNAs to select individuals or subpopulation of individuals for treatment with an anticancer therapy for multiple myeloma. Additional methods provided herein are useful for determining whether an individual in remission for multiple myeloma following successful treatment will be likely to suffer a relapse as well as to identify individuals who have suffered a relapse of multiple myeloma.



traducir


 

METHODS AND CHARACTERISTICS FOR THE DIAGNOSIS OF ACUTE LYMPHOBLASTIC LEUKEMIA

Nº publicación: US2016138115A1 19/05/2016

Solicitante:
SLOAN KETTERING INST CANCER [US]

Resumen de: WO2014205364A1

Methods for identification of leukemia or a genetic predisposition to leukemia are provided that are particularly applicable to acute lymphoblastic leukemia (ALL). A novel heterozygous germline variant, c.547G>A (p.Gly183Ser) in the octapeptide domain of PAX5, is used to identify those individuals with an enhanced risk or predisposition to ALL.



traducir


 

A METHOD OF DIAGNOSIS OR PROGNOSIS OF A NEOPLASM COMPRISING DETERMINING THE LEVEL OF EXPRESSION OF A PROTEIN IN STROMAL CELLS ADJACENT TO THE NEOPLASM

Nº publicación: US2016139132A1 19/05/2016

Solicitante:
UNIV JEFFERSON [US]

Resumen de: WO2010096574A1

The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I -delta, or M2- isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.



traducir


 

COMPOSITIONS AND METHODS FOR TREATING PRIMARY EFFUSION LYMPHOMA

Nº publicación: US2016136146A1 19/05/2016

Solicitantes:
CHAUDHARY PREET M [US]
GOPALAKRISHNAN RAMAKRISHNAN [US]
UNIV SOUTHERN CALIFORNIA [US]

Resumen de: US2016136146A1

Methods for treating primary effusion lymphoma (PEL) are provided. The methods include administering to a patient in need thereof an effective amount of an immunomodulatory compound. Suitable immunomodulatory compounds include compounds having the formula: wherein X in Formula IV may be independently selected from the group that includes hydrogen, a halide, an aliphatic group and an amine group.



traducir


 

DEEP SEQUENCING OF PERIPHERAL BLOOD PLASMA DNA AS A RELIABLE TEST FOR CONFIRMING THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME

Nº publicación: WO2016077408A1 19/05/2016

Solicitante:
NEOGENOMICS LAB INC [US]

Resumen de: US2016130648A1

Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum.



traducir


 

A METHOD OF DIAGNOSIS OR PROGNOSIS OF A NEOPLASM COMPRISING DETERMINING THE LEVEL OF EXPRESSION OF A PROTEIN IN STROMAL CELLS ADJACENT TO THE NEOPLASM

Nº publicación: EP3021120A1 18/05/2016

Solicitantes:
LISANTI MICHAEL P [US]
SOTGIA FEDERICA [US]
PESTELL RICHARD G [US]

Resumen de: WO2010096574A1

The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I -delta, or M2- isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.



traducir


 

DETECTING SEQUENCE MUTATIONS IN LEUKAEMIC FUSION GENES

Nº publicación: WO2016070230A1 12/05/2016

Solicitantes:
UNIV SOUTH AUSTRALIA [AU]
CENTRAL ADELAIDE LOCAL HEALTH NETWORK INC [AU]

Resumen de: WO2016070230A1

Methods of detecting mutations, particularly rare sequence mutations, within the kinase domain (KD) of a fusion gene comprising ABL1 are disclosed. These methods involve the use of a novel technique, termed Single Molecule Consensus Sequencing (SMCS). The methods particularly enable the detection of compound mutations present on the same BCR-ABL1 polynucleotide molecule that may be causative of an altered activity of an encoded protein, polypeptide or protein domain, which may in turn, be the cause of chronic myeloid leukaemia (CML) or acute lymphoblastic leukaemia (ALL) disease or, otherwise, of some disease- or treatment -associated characteristic (eg disease stage or drug resistance).



traducir


 

METHODS OF TREATING ACUTE MYELOID LEUKEMIA WITH A FLT3 MUTATION

Nº publicación: AU2014343214A1 12/05/2016

Solicitantes:
BIOLINERX LTD
BIOKINE THERAPEUTICS LTD

Resumen de: WO2015063768A1

There is provided a method of treating acute myeloid leukemia (AML). The method includes the step of administering to a patient having AML with a FMS-like tyrosine kinase 3 (FLT3)-mutation a therapeutically effective amount of a CXCR4- antagonistic peptide.



traducir


 

BIOLOGICAL MARKERS FOR IDENTIFYING IBRUTINIB RESISTANCE IN PATIENTS HAVING MANTLE CELL LYMPHOMA AND METHODS OF USING THE SAME

Nº publicación: WO2016071770A2 12/05/2016

Solicitante:
JANSSEN PHARMACEUTICA NV [BE]

Resumen de: WO2016071770A2

Disclosed herein are methods of predicting a likelihood of responsiveness to treatment with ibrutinib in a patient having mantle cell lymphoma and methods of treating a patient having mantle cell lymphoma.



traducir


 

METHODS TO DETECT IMMUNOGLOBULIN HEAVY CHAIN AND METHODS OF USE THEREOF

Nº publicación: WO2016072969A1 12/05/2016

Solicitantes:
TIAN ERMING [US]
EPSTEIN JOSHUA [US]
STEIN CALEB [US]

Resumen de: WO2016072969A1

The present invention provides a predictive model to determine treatment for subjects diagnosed with asymptomatic multiple myeloma.



traducir


 

COMPOSITIONS AND METHODS FOR TREATING MULTIPLE MYELOMA

Nº publicación: WO2016073184A1 12/05/2016

Solicitante:
DANA FARBER CANCER INST INC [US]

Resumen de: WO2016073184A1

The invention provides, inter alia, methods of prognosing the survival of a multiple myeloma patient based levels of TP53RK in multiple myeloma cells of the patient. Also provided are methods of screening for therapeutic agents for treating multiple myeloma based on their ability to decrease TP53RK levels or activity in a patient with multiple myeloma.



traducir


 

LKB1-AMPK ACTIVATORS FOR THERAPEUTIC USE IN POLYCYSTIC KIDNEY DISEASE

Nº publicación: WO2016073470A1 12/05/2016

Solicitante:
UNIV KANSAS [US]

Resumen de: WO2016073470A1

Compounds are provided for use in treating polycystic kidney disease (PKD) and in associated methods that include a method of modulating (e.g., activating) Liver kinase Bl (LKBI); and a method of modulating (e.g., decreasing activity) mammalian target of rapamycin (mTOR). The methods may include introducing the compound in a therapeutically effective amount to a subject having PKD. The methods may include introducing the compound in a therapeutically effective amount to a subject having Autosomal Dominant PKD. The compounds can be used in methods of treating a disease modulated by a mTOR pathway, which can include introducing the compound in a therapeutically effective amount to a subject having the disease modulated by the mTOR pathway. The disease modulated by mTOR is selected from the group consisting of multiple types of cancer, leukemia, kidney disease, obesity, neuro disorders and alcohol-related chronic diseases.



traducir


 

METHODS OF SELECTING AND ISOLATING CANCER STEM CELLS

Nº publicación: WO2016073737A1 12/05/2016

Solicitante:
UNIV CALIFORNIA [US]

Resumen de: WO2016073737A1

Provided herein are methods for selecting/identifying and/or isolating cancer stem cells from a biological sample or a cell culture sample using a fluorescent glucose analog. Also provided herein are methods for selecting/identifying and/or isolating leukemia stem cells and subpopulations thereof. The present invention is based, in part, on the discovery that cancer stem cells can be selected/identified based upon a lower level of fluorescence of the fluorescent glucose analog compared to non-cancer stem cells and that specific genes are differentially expressed in leukemia stem cells compared to non-leukemia stem cells.



traducir


 

DEEP SEQUENCING OF PERIPHERAL BLOOD PLASMA DNA AS A RELIABLE TEST FOR CONFIRMING THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME

Nº publicación: US2016130648A1 12/05/2016

Solicitante:
NEOGENOMICS LAB INC [US]

Resumen de: US2016130648A1

Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum.



traducir


 

USE OF COMPOSITIONS MODULATING CHROMATIN STRUCTURE FOR GRAFT VERSUS HOST DISEASE (GVHD)

Nº publicación: WO2016073903A1 12/05/2016

Solicitantes:
DANA FARBER CANCER INST INC [US]
UNIV MINNESOTA [US]

Resumen de: WO2016073903A1

In some aspects, the instant disclosure relates to methods of treating chronic graft versus host disease (cGVHD). In some embodiments, the method comprises administering to a subject in need thereof a EZH2 inhibitor, a Bcl6 inhibitor and/or BRD4 inhibitor. The present disclosure is based, at least in part, on the discovery that enhancer of zeste homolog 2 (EZH2) inhibitors, B-cell lymphoma 6 protein (Bcl6) inhibitors and/or bromodomain-containing protein 4 (BRD4) inhibitors can be used to treat chronic graft versus host disease (cGVHD).



traducir


 

SOLUBLE CD33 FOR TREATING MYELODYSPLASTIC SYNDROMES (MDS)

Nº publicación: EP3016512A2 11/05/2016

Solicitante:
H LEE MOFFITT CANCER CT & RES [US]

Resumen de: WO2015003149A2

Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.



traducir


 

MEANS AND METHODS FOR TREATING DLBCL

Nº publicación: EP3018145A1 11/05/2016

Solicitante:
AMGEN RES MUNICH GMBH [DE]

Resumen de: WO2012055961A1

The present invention provides means and methods for treating diffuse large B cell lymphoma (DLBCL). Specifically, a bispecific CD19 x CD3 antibody which engages T cells via its CD3 binding portion and concomitantly binds to CD19 on the surface of, in particular, lymphoma cells via its CD19 binding portion (i.e. a bispecific T cell engager, "BiTE") is administered for use in the treatment of tumorous mass of lymophoreticular tissue and/or extranodal lymphoma caused by DLBCL in a patient.



traducir


 

Use of Ibrutinib in treatment on FLT3-ITD mutation-caused acute leukemia

Nº publicación: WO2016065674A1 06/05/2016

Solicitante:
HEFEI INST PHYSICAL SCI CAS [CN]

Resumen de: CN104873515A

The invention discloses a novel use of Ibrutinib (PCI32765). Ibrutinib can be used for treating acute myelocytic leukemia and especially for treating acute myelocytic leukemia carrying a FLT3/ITD mutant gene.



traducir


 

TREATMENT OF PEDIATRIC BCP-ALL PATIENTS WITH AN ANTI-KIR ANTIBODY

Nº publicación: WO2016069589A1 06/05/2016

Solicitante:
UNIV CHILDREN S HOSPITAL T\u00DCBINGEN [DE]

Resumen de: WO2016069589A1

This disclosure provides a method for treating a pediatric subject afflicted with acute B cell precursor leukemia (BCP-ALL) comprising administering to the subject an anti-killer cell immunoglobulin-like receptor (KIR) antibody or an antigen-binding portion thereof that binds specifically to an inhibitory KIR and blocks inhibitory KIR activity, thereby potentiating NK cell lytic activity. An exemplary anti-KIR antibody for use in this method is lirilumab. The disclosure also provides a kit for treating a subject afflicted with pediatric BCP-ALL, the kit comprising a dosage ranging from 0.01 to 20 mg/kg body weight of an anti-KIR antibody or an antigen-binding portion thereof that specifically binds to an inhibitory KIR and blocks inhibitory KIR activity, and instructions for using the anti-KIR antibody or an antigen-binding portion thereof in any of the disclosed methods for treating pediatric BCP-ALL.



traducir


 

ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES

Nº publicación: WO2016070089A2 06/05/2016

Solicitante:
ABBVIE BIOTHERAPEUTICS INC [US]

Resumen de: WO2016070089A2

The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.


traducir



 

Página 1 de 3 nextPage Mostrar por página

Volver